Tenaya Therapeutics, Inc. (TNYA): Capital Expenditures
$618.0K
Year ended 2025-12-31
$263.0K
Trailing 12 months to 2026-06-30
-68.9%
3-year compound annual growth
-42.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $618.0K | -39.7% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $1.02M | -17.3% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $1.24M | -94.0% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $20.63M | -17.9% | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | $25.12M | +157.3% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $9.76M | n/a | 2022-03-23, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | 2025-12-31 | $618.0K | -39.7% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $31.0K | -98.8% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2024-12-31 | $0 | -100.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Compugen Ltd (CGEN) | 2025-12-31 | $306.0K | +159.3% |
| Palisade Bio, Inc. (PALI) | 2024-12-31 | $0 | -100.0% |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $2.59M | +303.0% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $1.23M | -44.4% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $99.0K | n/a |
Compare TNYA, INBX, BDTX, DTIL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗